Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS) Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms defined by morphologic dysplasia, peripheral cytopenia, and clonal instability with enhanced risk to transform into secondary acute myeloid leukaemia (AML). The prognosis and clinical picture in MDS vary depending on the variant of disease, cell types affected and genes involved in the malignant process. In fact, more and more data suggest that cytogenetic and molecular defects and gene-variants are associated with the clinical course and prognosis. The current article provides a short summary of our knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/clinical-impact-of-genetic-and-molecular-markers-in-myelodysplastic-EavIYyW7tW
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0098-6
Publisher site
See Article on Publisher Site

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms defined by morphologic dysplasia, peripheral cytopenia, and clonal instability with enhanced risk to transform into secondary acute myeloid leukaemia (AML). The prognosis and clinical picture in MDS vary depending on the variant of disease, cell types affected and genes involved in the malignant process. In fact, more and more data suggest that cytogenetic and molecular defects and gene-variants are associated with the clinical course and prognosis. The current article provides a short summary of our knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • Proposals for the classification of the myelodysplastic syndromes
    Bennett, JM; Catovsky, D; Daniel, MT; Flandrin, G
  • World health organization classification of tumours
    Brunning, RD; Bennett, JM; Flandrin, G; Matutes, E
  • Chromosome and molecular abnormalities in myelodysplastic syndromes
    Fenaux, P
  • Myelodysplastic syndrome
    Hofmann, WK; Koeffler, HP
  • Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference
    Valent, P; Horny, HP; Bennett, JM; Fonatsch, C
  • Myelodysplastic syndromes
    Nimer, SD
  • Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system
    Aul, C; Gattermann, N; Heyll, A; Gerrming, U
  • Myelodysplastic syndromes: a scoring system with prognostic significance
    Mufti, GJ; Stevens, JR; Oscier, DG; Hamblin, TJ
  • Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan
    Toyama, K; Ohyashiki, K; Yoshida, Y; Abe, T
  • International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P; Cox, C; LeBeau, MM; Fenaux, P
  • Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    Malcovati, L; Germing, U; Kündgen, A; Della Porta, MG
  • Myelodysplastic syndrome: review of the cytogenetic and molecular data
    Mhawech, P; Saleem, A
  • New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
    Haase, D; Germing, U; Schanz, J; Pfeilstöcker, M
  • Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies
    Giagounidis, AA; Germing, U; Aul, C
  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    List, A; Dewald, G; Bennett, JM; Giagounidis, AA
  • A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Cutler, CS; Lee, SJ; Greenberg, P; Deeg, HJ
  • Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary leukemias: a report on behalfe of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    de Witte, T; Hermans, J; Vossen, J; Bacigalupo, A
  • Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome
    Jaju, RJ; Boultwood, J; Oliver, FJ; Kostrzewa, M
  • Molecular cytogenetics localizes two new breakpoints on 11q23. 3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation
    Wlodarska, I; Selleri, L; La Starza, R; Paternotte, C
  • Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders
    Döhner, K; Brown, J; Hehmann, U; Hetzel, C
  • Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG)
    Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL
  • The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence
    Kurokawa, M; Ogawa, S; Tanaka, T; Mitani, K
  • Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias
    Tanaka, T; Mitani, K; Kurokawa, M; Ogawa, S
  • Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26
    Morishita, K; Parganas, E; William, CL; Whittaker, MH
  • EVI1 induces myelodysplastic syndrome in mice
    Buonamici, S; Li, D; Chi, Y; Zhao, R
  • The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells
    Kurokawa, M; Mitani, K; Imai, Y; Ogawa, S
  • The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3
    Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T
  • Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26)
    Reiter, E; Greinix, H; Rabitsch, W; Keil, F
  • Hematologic and clinical features of 3q21q26 syndrome: extremely poor prognosis and association with central diabetes insipidus
    Chung, HJ; Seo, EJ; Kim, KH; Jang, S
  • Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3)(q21;q26) positive AML
    Weisser, M; Haferlach, C; Haferlach, T; Schnittger, S
  • Biology and clinical features of myeloid neoplasms with inv(3)(q21q26) or t(3;3)(q21q26)
    Sperr, W; Valent, P
  • TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13)
    Wlodarska, I; Mecucci, C; Marynen, P; Guo, C
  • The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
    Carroll, M; Tomasson, MH; Barker, GF; Golub, TR; Gilliland, DG
  • Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta
    Steer, EJ; Cross, NC
  • Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Apperley, JF; Gardembas, M; Melo, JV; Russell-Jones, R
  • Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome
    Boultwood, J; Fidler, C; Strickson, AJ; Watkins, F
  • Identification of RPS14 as a 5q-syndrome gene by RNA interference screen
    Ebert, BL; Pretz, J; Bosco, J; Chang, CY
  • A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome
    Hirai, H; Kobayashi, Y; Mano, H; Hagiwara, K
  • Mutations of the Kirsten-ras proto-oncogene in human preleukaemia
    Liu, E; Hjelle, B; Morgan, R; Hecht, F; Bishop, JM
  • Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Kurzrock, R; Albitar, M; Cortes, JE; Estey, EH
  • Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies
    Gore, SD
  • The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
    Steensma, DP; Dewald, GW; Lasho, TL; Powell, HL
  • The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients
    Ohyashiki, K; Aota, Y; Akahane, D; Gotoh, A
  • The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
    Ingram, W; Lea, NC; Cervera, J; Germing, U
  • High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600×109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable
    Gattermann, N; Billiet, J; Kronenwett, R; Zipperer, E
  • Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
    Szpurka, H; Tiu, R; Murugesan, G; Aboudola, S
  • Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
    Fritsche-Polanz, R; Jordan, JH; Feix, A; Sperr, WR
  • Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature
    Bernd, HW; Sotlar, K; Lorenzen, J; Osieka, R
  • Mastocytosis: state of the art
    Horny, HP; Sotlar, K; Valent, P
  • Systemic mastocytosis
    Valent, P
  • Familial myelodysplasia and acute myeloid leukaemia – a review
    Owen, C; Barnett, M; Fitzgibbon, J
  • High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest study on 50 patients
    Várkonyi, J; Tarkovács, G; Karádi, I; Andrikovics, H
  • Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts
    Nearman, ZP; Szpurka, H; Serio, B; Warshawksy, I
  • The significance of the hemochromatosis genetic variants in multiple myeloma in comparison to that of myelodysplastic syndrome
    Várkonyi, J; Demeter, J; Tordai, A; Andrikovics, H
  • Myelodysplastic syndromes: iron overload consequences and current chelating therapies
    Greenberg, PL
  • Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
    Malcovati, L
  • Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
    Valent, P; Krieger, O; Stauder, R; Wimazal, F
  • Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
    Hofmann, WK; de Vos, S; Komor, M; Hoelzer, D
  • Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology
    Pellagatti, A; Esoof, N; Watkins, F; Langford, CF
  • Gene expression profiling in the myelodysplastic syndromes
    Pellagatti, A; Fidler, C; Wainscoat, JS; Boultwood, J